Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Monica Giovannini, Vanesa Gregorc, Carmen Belli, Elisa Roca, Chiara Lazzari, Maria Grazia Viganò, Anna Serafico, Eugenio Villa, Monica Giovannini, Vanesa Gregorc, Carmen Belli, Elisa Roca, Chiara Lazzari, Maria Grazia Viganò, Anna Serafico, Eugenio Villa

Abstract

Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven.

References

    1. Clark GM, Pèrez-Soler R, Siu L, Gordon A, Santabárbara P. Rash severity is predictive of increased survival with erlotinib HCI. In: Proceedings of the American Society of Clinical Oncology (ASCO '03), vol. 22; June 2003; Chicago, Ill, USA. p. 196.
    1. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. In: Proceedings of the American Society of Clinical Oncology (ASCO '03), vol. 22; June 2003; Chicago, Ill, USA. p. 204.
    1. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. Journal of Clinical Oncology. 2002;20(9):2240–2250.
    1. Herbst R, Maddox A-M, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology. 2002;20(18):3815–3825.
    1. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Journal of Clinical Oncology. 2001;19(13):3267–3279.
    1. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. International Journal of Gynecological Cancer. 2005;15(5):785–792.
    1. Pérez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology. 2003;17(11) supplement 12:23–28.
    1. Tewesk M, Schleucher N, Dirsch O, et al. Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. In: Proceedings of the American Society of Clinical Oncology (ASCO '), vol. 20; May 2001; San Francisco, Calif, USA. p. 378.
    1. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. Journal of Clinical Oncology. 2001;19(13):3234–3243.
    1. Food and Drug Administration, .
    1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology. 2003;21(14):2787–2799.
    1. EMEA, .
    1. EMEA, .
    1. Food and Drug Administration, , EMEA, .
    1. Food and Drug Administration, .
    1. EMEA, .
    1. Food and Drug Administration, .
    1. EMEA, .
    1. Food and Drug Administration, .
    1. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology. 2006;55(4):657–670.
    1. Bruno R, Mass RD, Jones C, Lu J-F, Winer E. Preliminary population pharmacokinetics (PPK) and exposure-safety (E-S) relationships of erlotinib HCI in patients with metastatic breast cancer (MBC). In: Proceedings of the American Society of Clinical Oncology (ASCO '03), vol. 22; June 2003; Chicago, Ill, USA. p. 205.
    1. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Seminars in Oncology Nursing. 2006;22(supplement 1):28–34.
    1. Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. British Journal of Dermatology. 2006;155(4):852–854.
    1. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology. 2005;16(9):1425–1433.
    1. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology. 2001;144(6):1169–1176.
    1. Jost M, Kari C, Rodeck U. The EGF receptor—an essential regulator of multiple epidermal functions. European Journal of Dermatology. 2000;10(7):505–510.
    1. Nanney LB, Stoscheck CM, King LE, Jr., Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. Journal of Investigative Dermatology. 1990;94(6):742–748.
    1. Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology. 2006;20(5) supplement 2:26–34.
    1. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. Journal of Investigative Dermatology. 1997;109(6):751–756.
    1. Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases epxression of genes that stimulate inflammation, apoptosis, and cell attachment. Molecular Cancer Therapeutics. 2005;4(4):650–658.
    1. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Seminars in Oncology Nursing. 2006;22(supplement 1):28–34.
    1. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer. 2006;6(10):803–812.
    1. Mitra SS, Simcock R. Erlotinib induced skin rash spares skin in previous radiotherapy field. Journal of Clinical Oncology. 2006;24(16):e28–e29.
    1. Giovannini M, Gregorc V, Viganò MG, et al. Endothelial growth factor receptor inhibition after radiotherapy. Journal of Thoracic Oncology. 2007;2(7):p. 662.
    1. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. In: Proceedings of the American Society of Clinical Oncology (ASCO '07), vol. 25; June 2007; Chicago, Ill, USA. p. 172s. abstact 4035.
    1. Van Cutsem E, Nowacki M, Lang S, et al. Randomized phase III study of irinotecan and 5FU/FA with or without cetuximab in the first line treatment of patients with colorectal cancer: the Crystal study. In: Proceedings of the American Society of Clinical Oncology (ASCO '07), vol. 25; June 2007; Chicago, Ill, USA. p. 164s. abstract 4000.
    1. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology. 2004;22(7):1201–1208.
    1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. The New England Journal of Medicine. 2004;351(4):337–345.
    1. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology. 2004;22(7):1201–1208.
    1. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008;26(14):2311–2319.
    1. Jonker DJ, Karapetis CS, Moore M, et al. Randomized phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; April 2007; Los Angeles, Calif, USA.
    1. Tejpar M, Peeters Y, Humblet H, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Journal of Clinical Oncology. 2007;25(18, supplement) abstract 4037.
    1. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. Journal of Clinical Oncology. 2004;22(13):2610–2616.
    1. Bonner JA, Harari PM, Giralt J, et al. The Relationship of Cetuximab-Induced Rash and Survival in Patients with Head and Neck Cancer Treated with Radiotherapy and Cetuximab. International Journal of Radiation Oncology, Biology, Physics. 2005;63(supplement 1):p. s73.
    1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2003;21(12):2237–2246.
    1. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. The Journal of the American Medical Association. 2003;290(16):2149–2158.
    1. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Annals of Oncology. 2005;16(5):780–785.
    1. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology. 2003;21(10):1980–1987.
    1. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clinical Cancer Research. 2007;13(13):3913–3921.
    1. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarvala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of Clinical Oncology. 2004;22(1):77–85.
    1. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology. 2007;25(13):1658–1664.
    1. Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clinical Colorectal Cancer. 2008;7(2):144–148.
    1. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute. 2006;98(23):1739–1742.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel